CLINICAL NEWS |
|||
In eight of the 14 ( 57 %), anti-leukemic activity was observed , including six who met International Working Group response criteria ., for an overall response rate of 43 percent .
Two patients had stable disease and bone marrow blast reduction of 20 percent and 25 percent from baseline , respectively . Also , Dr . Uy added , “ when we looked at patients who received doses above 500 nanograms , we saw about
|
40 to 50 percent of the patients having some evidence of anti-leukemic activity , with about 20 to 30 percent of the patients having measurable responses .” While the results from this earlyphase study will need to be confirmed in larger , randomized trials , they “ support the role for this immune-activating agent in treating AML .” The study continues to enroll patients .
“ The lack of response may be because
|
certain patients do not express the tumor antigen on their leukemic cells , or because these tumors are able to evade the patient ’ s own immune system , so we are investigating whether checkpoint inhibitors can augment the effects of flotetuzumab ,” he said . “ Next , we are looking at ways to mitigate CRS risk , through better dose optimization , changing dosing schedules , or adding additional agents and different antibodies to different cytokines .” |
The authors report financial relationships with MacroGenics , the manufacturer of flotetuzumab .
REFERENCE
Uy GL , Godwin J , Rettig MP , et al . Preliminary results of a phase 1 study of flotetuzumab , a CD123 ´ CD3 bispecific Dart ® protein , in patients with relapsed / refractory acute myeloid leukemia and myelodysplastic syndrome . Abstract # 637 . Presented at the 2017 American Society of Hematology Annual Meeting , December 11 , 2017 ; Atlanta , GA .
|